CALGB 20203: Molecular Markers of Chronic Lymphocytic Leukemia (Barbara Grant, MD).
CALGB 50203: A Phase II trial of Doxorubicin, Vinblastine and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin Lymphoma (Barbara Grant, MD).
CALGB 50202: Intensive Chemotherapy and Immumotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (Barbara Grant, MD).
CALGB 10101: A Phase II Study of Fludarabine and Rituximab Induction Followed by Alemtuzumab (Campath-1H, NSC # 715969, IND # 10864) Consolidation in Untreated Patients with B-Cell Chronic Lymphocytic Leukemia (Barbara Grant, MD).
C30306: Cisplatin, irenotecan, and bevacizumab for untreated extensive stage small cell lung cancer. A phase II study.
NSABP 38: A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/ Cyclophosphamide (TAC); Dose Dense (DD) Doxorubicin/Chyclophosphamide Followed by DD Paclitaxel (DD>P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC> PG).
RTOG 0420: A Phase II Study of Radiation Therapy Plus Low Dose Temozolomide Followed by Temozolomide Plus Irinotecan for Glioblastoma Multiforme (James Wallace, MD).
RTOG 0324: A Phase II Study of Cetuximab (C225) in Combination with Chemoradiation in Patients with Stage IIIA/B Non- Small Cell Lung Cancer. (Steve Grunberg, MD).
V0406: Platelet Subpopulations and Function in Patients with Hematologic and Oncologic Disorders.
For more information about these studies, call Holli McFadden, Clinical Trials Office, at 802-656-2178.